NASDAQ · IMGN
Healthcare · Biotechnology
$31.24
Up+$0.01 (+0.02%)
Updated Aug 13, 2026, 9:47 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
IMGN does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning IMGN.
IMGN research
Company profile and research snapshot.
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 4, 2023 | Piper Sandler | Neutral | — |
| Dec 4, 2023 | Barclays | Equal-Weight | — |
| Dec 1, 2023 | Barclays | Equal-Weight | — |
| Dec 1, 2023 | Jefferies | Hold | — |
| Dec 1, 2023 | Guggenheim | Neutral | — |
No generated briefing is available yet.
Zacks Investment Research · Feb 9, 2024
The FDA bestows a Fast Track designation to Ionis (IONS) and partner AstraZeneca's (AZN) eplontersen for treating adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
Zacks Investment Research · Feb 9, 2024
Here is how ImmunoGen (IMGN) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.
Zacks Investment Research · Feb 9, 2024
ImmunoGen (IMGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks Investment Research · Feb 8, 2024
Bristol Myers (BMY) announces the acceptance of its regulatory filings for the perioperative Opdivo regimen to treat a lung cancer indication in the United States and EU.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IMGN.
No results
No recent SID articles mention IMGN.
